Sugi Predict

Sugi Predict / Compounds / SCHEMBL20135162

SCHEMBL20135162

SCHEMBL20135162

O=C1NC(=O)C(c2ccc(C(=O)O)cc2)(C(F)(F)F)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ TTR P02766 1/20 0.37
▸ METAP1 P53582 1/20 0.36
▸ AKR1B1 P15121 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ MMP2 P08253 2/20 0.35
▸ MMP8 P22894 1/20 0.35
▸ MMP3 P08254 1/20 0.35
▸ MMP9 P14780 1/20 0.35
▸ MMP13 P45452 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CACNA1F O60840 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134813 0.84 RXRA (0.38) SRD5A2TP53TSHRTTRMETAP1
SCHEMBL14101183 0.82 CYP2C9 (0.53) AKR1B1MMP2MMP9ALDH1A1CACNA1F
SCHEMBL20134906 0.80 CA1 (0.37) SRD5A2TP53TSHRMETAP1AKR1B1
SCHEMBL20135320 0.76 CA1 (0.34) SRD5A2METAP1AKR1B1MEN1KMT2A
SCHEMBL1968442 0.75 TSHR (0.48) TSHRAKR1B1MMP2MMP8MMP9
SCHEMBL11411411 0.75 CYP2C9 (0.63) SRD5A2TP53TSHRMETAP1AKR1B1
SCHEMBL20135237 0.75 ADAMTS5 (0.42) MMP2MMP8MMP9MMP13
SCHEMBL20135641 0.73 TSHR (0.39) SRD5A2TP53TSHRTTRMETAP1
SCHEMBL20134880 0.72 MEN1 (0.55) SRD5A2TP53TSHRMETAP1AKR1B1
SCHEMBL4308515 0.72 MEN1 (0.55) SRD5A2TP53TSHRMETAP1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 SRD5A2 2668/4885TP53 4082/4885TSHR 3522/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 SRD5A2 2568/4885TP53 3806/4885TSHR 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.